NASDAQ:SYRE Spyre Therapeutics (SYRE) Stock Price, News & Analysis $90.25 -2.43 (-2.62%) Closing price 09/18/2026 04:00 PM EasternExtended Trading$90.30 +0.05 (+0.05%) As of 09/18/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Spyre Therapeutics Stock (NASDAQ:SYRE) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Spyre Therapeutics alerts:Sign Up Key Stats Today's Range$89.85▼$93.3450-Day Range$86.93▼$108.9252-Week Range$14.51▼$110.18Volume3.36 million shsAverage Volume1.17 million shsMarket Capitalization$7.94 billionP/E RatioN/ADividend YieldN/APrice Target$109.69Consensus RatingModerate Buy Company Overview Spyre Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing next-generation antibody therapies for inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis. The company’s approach is designed to address significant treatment needs in chronic immune-mediated conditions through therapies with potentially improved efficacy, durability and dosing convenience. Spyre’s pipeline includes investigational antibody programs targeting biological pathways associated with IBD, including interleukin-23 (IL-23), TL1A and integrin-mediated immune activity. Its development strategy combines these targeted medicines with biomarker-driven research and combination approaches intended to improve disease control and patient outcomes. The company’s product candidates remain investigational and are subject to clinical testing and regulatory review. Spyre was created through the combination of private Spyre Therapeutics and Aeglea BioTherapeutics, with the transaction resulting in the public company’s current name and Nasdaq listing under the symbol SYRE. The company is headquartered in the United States and conducts research and clinical-development activities for its IBD programs, including through clinical studies that may involve patients and research sites in multiple geographies.AI Generated. May Contain Errors. Read More Spyre Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks55th Percentile Overall ScoreSYRE MarketRank™: Spyre Therapeutics scored higher than 55% of companies evaluated by MarketBeat, and ranked 408th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingModerate Buy Consensus RatingSpyre Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.87, and is based on 1 strong buy rating, 12 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialSpyre Therapeutics has a consensus price target of $109.69, representing about 21.5% upside from its current price of $90.25.Amount of Analyst CoverageSpyre Therapeutics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Spyre Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Spyre Therapeutics are expected to decrease in the coming year, from ($2.71) to ($3.70) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Spyre Therapeutics is -46.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Spyre Therapeutics is -46.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSpyre Therapeutics has a P/B Ratio of 12.52. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Spyre Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted16.00% of the float of Spyre Therapeutics has been sold short.Short Interest Ratio / Days to CoverSpyre Therapeutics has a short interest ratio ("days to cover") of 9.69.Change versus previous monthShort interest in Spyre Therapeutics has recently increased by 0.89%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSpyre Therapeutics does not currently pay a dividend.Dividend GrowthSpyre Therapeutics does not have a long track record of dividend growth. News and Social Media3.2 / 5News Sentiment1.11 News SentimentSpyre Therapeutics has a news sentiment score of 1.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Spyre Therapeutics this week, compared to 5 articles on an average week.Search InterestOnly 1 people have searched for SYRE on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Spyre Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Company Ownership2.0 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Spyre Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $16,638,714.00 in company stock.Percentage Held by Insiders15.69% of the stock of Spyre Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions80.39% of the stock of Spyre Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Spyre Therapeutics' insider trading history. Receive SYRE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Spyre Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SYRE Stock News HeadlinesSpyre Therapeutics, Inc. (NASDAQ:SYRE) Given Consensus Rating of "Moderate Buy" by BrokeragesSeptember 20 at 3:15 AM | americanbankingnews.comSpyre (SYRE) Clears Monotherapy Phase for IBD Portfolio, Setting Up Combination TestsSeptember 17 at 9:20 AM | finance.yahoo.comHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.September 20 at 1:00 AM | Stansberry Research (Ad)Financial Contrast: Spyre Therapeutics (NASDAQ:SYRE) vs. Genmab A/S (NASDAQ:GMAB)September 17 at 4:44 AM | americanbankingnews.comSpyre Therapeutics (NASDAQ:SYRE) Earns Outperform Rating from WedbushSeptember 11, 2026 | americanbankingnews.comSpyre Therapeutics (SYRE) Reports SPY003 Endoscopic Improvement. Can Randomized Testing Confirm It?September 10, 2026 | insidermonkey.comSpyre Therapeutics (NASDAQ:SYRE) Earns Buy Rating from BTIG ResearchSeptember 10, 2026 | americanbankingnews.comSpyre Therapeutics (NASDAQ:SYRE) Insider Heidy King-Jones Sells 400 Shares of StockSeptember 4, 2026 | insidertrades.comSee More Headlines SYRE Stock Analysis - Frequently Asked Questions How have SYRE shares performed this year? Spyre Therapeutics' stock was trading at $32.76 at the start of the year. Since then, SYRE stock has increased by 175.5% and is now trading at $90.25. How were Spyre Therapeutics' earnings last quarter? Spyre Therapeutics, Inc. (NASDAQ:SYRE) posted its earnings results on Tuesday, August, 4th. The company reported ($0.36) earnings per share for the quarter, topping analysts' consensus estimates of ($0.76) by $0.40. When did Spyre Therapeutics IPO? Spyre Therapeutics (SYRE) raised $85 million in an initial public offering on Wednesday, April 6th 2016. The company issued 5,000,000 shares at a price of $16.00-$18.00 per share. Who are Spyre Therapeutics' major shareholders? Spyre Therapeutics' top institutional shareholders include Wellington Management Group LLP (1.80%), Braidwell LP (1.00%), Bank of New York Mellon Corp (0.28%) and Squarepoint Ops LLC (0.16%). Insiders that own company stock include Cameron Turtle, Scott L Burrows, Michael Thomas Henderson, Sheldon Sloan, Jeffrey W Albers, Heidy King-Jones and Fairmount Funds Management Llc. View institutional ownership trends. How do I buy shares of Spyre Therapeutics? Shares of SYRE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Spyre Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Spyre Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), ServiceNow (NOW) and Arista Networks (ANET). Company Calendar Last Earnings8/04/2026Today9/20/2026Stifel 2026 Virtual Immunology and Inflammation Forum9/23/2026Next Earnings (Estimated)11/03/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (10m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 SYRE's financial health is in the Green zone, according to TradeSmith. SYRE has been in this zone for over 10 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:SYRE Previous SymbolNASDAQ:SYRE CIK1636282 Webwww.spyre.com Phone(617) 651-5940Fax512-872-5121Employees112Year Founded2013Price Target and Rating Average Price Target for Spyre Therapeutics$109.69 High Price Target$130.00 Low Price Target$80.00 Potential Upside/Downside+21.5%Consensus RatingModerate Buy Rating Score (0-4)2.87 Research Coverage15 Analysts Profitability EPS (Trailing Twelve Months)($1.95) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$155.20 million Net MarginsN/A Pretax MarginN/A Return on Equity-30.74% Return on Assets-22.23% Debt Debt-to-Equity RatioN/A Current Ratio18.53 Quick Ratio18.53 Sales & Book Value Annual Sales$890 thousand Price / Sales8,917.51 Cash FlowN/A Price / Cash FlowN/A Book Value$7.21 per share Price / Book12.52Miscellaneous Outstanding Shares87,940,000Free Float74,139,000Market Cap$7.94 billion OptionableOptionable Beta2.99 The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:SYRE) was last updated on 9/20/2026 by MarketBeat.com Staff. From Our Partners$40,000,000,000,000The national debt just hit 40 trillion dollars, and the U.S. now spends more on interest payments than on its ...American Alternative | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredNVDA CEO says it’s a "once-in-a-generation opportunity"NVIDIA CEO Jensen Huang calls a little-known AI niche a once-in-a-generation opportunity, and it has nothing t...Monument Traders Alliance | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredIran War: Why Is Trump Protecting THEM?A powerful Middle Eastern government is reportedly seeking US intelligence, targeting help, and military prote...Banyan Hill Publishing | SponsoredNew Form of AI Could Ignite the ‘Great Wealth Rotation’Marc Chaikin, a 60-year Wall Street veteran who worked alongside Paul Tudor Jones and Steve Cohen, says a new ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Spyre Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Spyre Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
